MetaCap

Harmony Biosciences (HRMY) vs Vera Therapeutics (VERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Harmony Biosciences (HRMY) has outperformed Vera Therapeutics (VERA) over the past year, losing 5.0% versus a loss of 10.6%. Over five years, HRMY leads with a -13.2% price change compared with -15.2% for VERA. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.84 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HRMY-5.01%VERA-10.58%
+102%+36%-29%
Nov 21, 20251 yearNov 20, 2026
HRMY-15.92%VERA-18.43%
+79%-5%-90%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HRMY versus VERA key metrics
MetricHRMYVERA
Share price$32.59$25.45
Market cap$1.91B$1.84B
1-day change-1.18%-4.86%
YTD return-12.91%-49.74%
1-year return-5.01%-10.58%
5-year return-13.21%-15.17%
P/E ratio (TTM)10.79—
Forward P/E5.37—
EPS (TTM)$3.02$-5.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$868.45M—
Revenue growth (YoY)+21.51%—
Net income (latest FY)$158.69M$-299.62M
Gross margin77.16%—
Operating margin24.00%—
Net margin18.27%—
52-week high$43.49$56.05
52-week low$25.90$25.08
Distance from 52-week high-25.06%-54.59%
Analyst consensusbuystrong_buy
Avg. price target upside+47.53%+180.39%
Average volume1.01M1.95M
Shares outstanding58.72M72.30M
Employees293362
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Harmony Biosciences

HRMY stock →

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

About Vera Therapeutics

VERA stock →

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees

HRMY vs VERA FAQ

Which is bigger, Harmony Biosciences or Vera Therapeutics?

Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.84B for Vera Therapeutics (VERA).

Which stock has performed better over the past year, HRMY or VERA?

HRMY returned -5.01% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.

Are Harmony Biosciences and Vera Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons